SLGL News and Press, Sol-Gel Technologies Ltd. From 09/10/20

The FDA accepts for review Sol-Gel Technologies' (NASDAQ: SLGL ) marketing application seeking approval of Epsolay (benzoyl peroxide) topical cream for the treatment of inflammatory lesions associated with an acne-like skin condition called rosacea . More news on: Sol-Gel Technologies...

- PDUFA Goal Date Set for April 26, 2021 - Potential to be first FDA-approved single-agent benzoyl peroxide prescription drug product NESS ZIONA, Israel, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on ident...

NESS ZIONA, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases,&#x...

Patent challenge initiated by Bausch Health Companies NESS ZIONA, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug product...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . Economic reports in the week ahead Investors will have their eyes on economic reports covering construction spending, manufacturing a...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Sol-Gel Technologies (NASDAQ: SLGL ) : Q2 GAAP EPS of -$0.31 beats by $0.03 . More news on: Sol-Gel Technologies Ltd., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...

New Drug Application for Epsolay® Submitted; Twyneo® New Drug Application on track for 2H 2020 Top-line generic product revenue of $1.1 million in 2Q 2020 Launch of additional generic product expected in 2Q 2021 NESS ZIONA, Israel, Aug. 06, 2020 (GLOBE NEWSWIRE) --...

NESS ZIONA, Israel, July 29, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for...

NESS ZIONA, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that Sol...